A Phase 1, Open-label, Sequential-group, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 592 Administered Subcutaneously in Healthy Chinese, Japanese, and Caucasian Subjects
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Efavaleukin alfa (Primary)
- Indications Graft-versus-host disease; Inflammation; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Amgen
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.
- 24 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2022 Status changed from active, no longer recruiting to recruiting.